Target gene sequencing to define the susceptibility of Neisseria meningitidis to ciprofloxacin.
Meningococcal gyrA gene sequence data, MICs, and mouse infection were used to define the ciprofloxacin breakpoint for Neisseria meningitidis. Residue T91 or D95 of GyrA was altered in all meningococcal isolates with MICs of ≥ 0.064 μg/ml but not among isolates with MICs of ≤ 0.032 μg/ml. Experimental infection of ciprofloxacin-treated mice showed slower bacterial clearance when GyrA was altered. These data suggest a MIC of ≥ 0.064 μg/ml as the ciprofloxacin breakpoint for meningococci and argue for the molecular detection of ciprofloxacin resistance.
Institut Pasteur, Invasive Bacterial Infections Unit and National Reference Centre for Meningococci, Paris, France.
Eva
E
Hong
Sara
S
Thulin Hedberg
Raquel
R
Abad
Cecilia
C
Fazio
Rocío
R
Enríquez
Ala-Eddine
AE
Deghmane
Keith A
KA
Jolley
Paola
P
Stefanelli
Magnus
M
Unemo
Julio A
JA
Vazquez
Frédéric J
FJ
Veyrier
Muhamed-Kheir
MK
Taha
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002939:Ciprofloxacin; D027081:DNA Gyrase / Q000235:genetics / Q000378:metabolism*; D005260:Female; D008589:Meningococcal Infections / Q000188:drug therapy* / Q000382:microbiology*; D051379:Mice; D008822:Mice, Transgenic; D008826:Microbial Sensitivity Tests; D009345:Neisseria meningitidis / Q000187:drug effects* / Q000378:metabolism* / Q000472:pathogenicity
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002939:Ciprofloxacin; D027081:DNA Gyrase